Key questions about the PIMS® platform, its applications, and how it supports precision medicine.
Physiological Intermolecular Modulation Spectroscopy (PIMS®) is a patented, label-free biophysical technology that uses near-infrared (NIR) spectroscopy to monitor molecular interactions in their native state. By using the resonance of water molecules as a natural probe, PIMS® detects subtle nanoscale conformational changes when a drug interacts with its target within actual human pathological samples. This provides a functional "fingerprint" of drug-target engagement that traditional assays cannot capture.
Traditional "Omics" provides a static "parts list" — identifying which molecules are present but failing to show how they behave. PIMS® delivers The Truth in the Tissue by capturing the functional "intermolecular conversation" in real-time. While genomics and proteomics describe molecular composition in artificial buffers, PIMS® uses the physics of water resonance to measure actual drug-target engagement within native, pathological environments. We don't just identify the players; we provide a dynamic readout of the game, allowing developers to see if a drug actually works in a specific patient's tissue before the trial even begins.
A major challenge in clinical development is patient heterogeneity: patients with the same diagnosis often respond very differently to the same treatment. This variability can dilute efficacy signals and increase the risk of late-stage trial failure. PIMS® addresses this challenge by enabling functional assessment of drug response at the sample level, supporting better-informed patient stratification and trial design decisions.
PIMS® is a versatile, indication-agnostic platform. It has already demonstrated high accuracy in Immunology, particularly in predicting responses for inflammatory bowel disease therapies. In Oncology, it excels at profiling metastatic colorectal cancer and predicting response to monoclonal antibodies. The technology can also be applied to neurology, rare diseases, and various inflammatory conditions.
PIMS® serves as a powerful tool for clinical de-risking by identifying responders and non-responders before and during a clinical trial. By stratifying patient cohorts ex vivo, companies can reduce clinical attrition rates, optimize trial size, and significantly decrease the high costs associated with clinical failure.
The platform is designed for maximum clinical utility, requiring minimal sample preparation. It is compatible with primary cells such as PBMCs, solid tissue biopsies, and liquid phase samples including plasma, serum, and whole blood. This flexibility allows PIMS® to be integrated into existing clinical workflows without specialized sampling requirements.
PIMS® is target-agnostic. Because it measures the "intermolecular modulation" of the entire physiological environment using water as a probe, it does not require a pre-defined molecular target or a known biomarker to identify a responder. This makes it exceptionally powerful for complex therapies, such as multi-target compounds, phenotypic drug discovery, or cases where the exact Mechanism of Action (MoA) is still being elucidated. We provide a functional readout of the drug's total impact on the patient's native tissue.
PIMS® provides an immediate functional readout that traditional phenotypic monitoring cannot match. While clinical monitoring often requires months of patient observation to determine drug efficacy, the PIMS® Q8 platform delivers real-time molecular insights. The raw analysis is high-throughput, processing 8 samples in just 20 minutes.
When including data interpretation, PIMS® provides a definitive "Responder vs. Non-Responder" stratification in a fraction of the time required for deep-sequencing Omics or digital twin modeling. This speed allows drug developers to optimize cohorts and pivot strategies in weeks, not years, significantly reducing the "Time-to-Decision."
By helping identify biological non-responders and monitor functional response over time, PIMS® supports approaches that reduce unnecessary exposure to ineffective treatments in clinical trials. This aligns with ethical principles of patient protection and more individualized evaluation of therapeutic benefit.
Yes. Beyond initial patient stratification, the PIMS® platform is a vital tool for Adaptive Therapy Design. By analyzing samples taken at different intervals during a trial, we can monitor the evolution of the molecular "fingerprint" in real-time. This allows clinical sponsors to detect the early onset of molecular resistance, enabling faster decision-making and more personalized treatment adjustments for the patient.
PIMS Technology originated as a spin-off from Inoviem Scientific to focus on the industrialization and deployment of the PIMS® platform. The two organizations remain scientifically complementary and positioned as strategic partners, while operating as independent entities with distinct missions.
Our technology is secured by a robust international intellectual property with granted patents in major global markets, together with a unique know-how. Scientific validation is supported by multiple peer-reviewed publications demonstrating predictive accuracy rates as high as ninety to one hundred percent in specific patient groups, proving the platform's reliability to the scientific community.
PIMS Technology offers a flexible, modular business model designed to align with the specific R&D requirements of Biopharma, SMEs, and Clinical Research Centers. We move beyond a simple vendor-client relationship to become a strategic partner through:
Our vision is to define the next era of drug development by establishing a new functional standard for biological assessment. We are currently scaling our roadmap to include AI-driven spectral interpretation modules that automate the transformation of complex H₂O resonance signals into actionable clinical data. By merging the precision of physics with the scale of machine learning, PIMS® will serve as a global reference engine for molecular behavior. This transition replaces trial-and-error methodologies with data-driven protocols, ultimately making personalized medicine a scalable, deterministic reality for every clinical trial.
Discuss how functional stratification could support your programmes.